ABSTRACT
Objective To analyze the expression and clinicopathological significance of seven in absentia homolog 2 (SIAH2) in epithelial ovarian carcinoma, and to discuss its role in the development of epithelial ovarian carcinoma. Methods The expression of SIAH2 was determined by immunohistochemical S-P method in 165 cases of ovarian samples and SIAH2 expression was examined by Western blot. In the combination with follow-up data, survival curves were calculated using the Kaplan-Meier method and relationship between SIAH2 expression and prognosis of ovarian carcinoma patients was analyzed by the log-rank test. Cox proportional hazards regression model was used to examine the independent predictive factors in the patients with epithelial ovarian carcinoma.Results SIAH2 expression in epithelial ovarian cancer (76.4％) was higher than that of borderline ovarian tumors (41.7％) , benign ovarian cysts (5.13％) and normal ovarian tissues (2.86％) , and there were significant differences (all P < 0.05). No statistical significance of SIAH2 expression was found between benign ovarian cysts and normal ovarian tissues (P> 0.05). The expression of the SIAH2 was significantly correlated to histological grade, FIGO stage and lymph node metastasis (P < 0.05).The relative expression of SIAH2 in normal ovarian tissue, benign ovarian cyst, borderline ovarian tumor and epithelial ovarian cancer was 0.12 ± 0.05, 0.11 ± 0.04, 0.57 ± 0.08 and 1.05 ± 0.10, respectively. No difference of SIAH2 expression was found between normal ovarian tissues and benign ovarian cysts (P> 0.05). The expression of SIAH2 increased from ovarian tissues/benign ovarian cysts to borderline ovarian tumor to epithelial ovarian cancer and the difference was statistically significant (all P < 0.05).The survival curves of patients with SIAH2 (+) differed from those of patients with SIAH2 (-) and the difference was statistically significant (P < 0.05). Multiple factor analysis revealed that the higher expression of SIAH2 was an independent prognostic factor for overall survival. Conclusions The over-expression of SIAH2 plays an important role in the tumorigenesis and progression of epithelial ovarian cancer. The over-expression of SIAH2 may serve as a biomarker for poor prognosis of epithelial ovarian cancer patients.
ABSTRACT
Objective: To investigate the prognostic value of SIAH2 expression in laryngeal squamous cell carcinoma (LSCC). Methods: The qualitative expression of SIAH2 in 119 laryngeal tissues was studied by immunohistochemical staining. Western blot was used to examine the quantitative expression of SIAH2. Survival rates were calculated using the Kaplan-Meier method. Correlation between SIAH2 expression and LSCC patients'prognosis was analyzed by the Log-rank test. The Cox proportional hazards regression model was used to examine the independent predictive factors of LSCC. Results: The SIAH2 expression in LSCC (77.19%) was higher than that in the laryngeal atypical hyperplasia (53.13%) and normal laryngeal tissues (26.67%), and significant differences were observed (χ2=21.02, P=0.000). The expression of SIAH2 was significantly correlated to the histological grade, clinical stage, and lymph node metastasis (P<0.05). The relative expression of SIAH2 in normal laryngeal tissue (1.25±0.04), laryngeal atypical hyperplasia (1.38 ± 0.05), and LSCC (1.44±0.07) was observed to increase gradually (F=61.811, P<0.001). The 5-year survival rate of SIAH2 (+) and SIAH2 (-) patients was 18.18% and 58.33%, respectively (χ2=5.720, P=0.017), and the median survival time of SIAH2 (+) and SIAH2 (-) patients was 25 and 60 months, respectively (P<0.05 ). The multivariate regression analysis revealed that the higher expression of SIAH2 was an independent prognostic factor for the overall survival. Conclusions:SIAH2 may be involved in the tumorigenesis and progression of LSCC as an oncogene. Overexpression of the marker indicated poor prognosis of the disease, a finding which might allow SIAH2 to be used as a potential target gene for the treatment of LSCC.